Glioblastoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight

DelveInsight's, "Glioblastoma Pipeline Insight" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioblastoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Glioblastoma pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Glioblastoma Pipeline Report to explore emerging therapies, key Glioblastoma Companies, and future Glioblastoma treatment landscapes @ Glioblastoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Glioblastoma Pipeline Report

* In February 2025:- NovoCure GmbH :- This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune Registered (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune Registered together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
* In January 2025:- NuvOx LLC:- This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.
* In January 2025:- Philogen S.p.A :- The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence
* In January 2025:- Genenta Science:- This is a non-randomized, open label, phase I/IIa, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor cells exposed to transduction with a lentiviral vector driving myeloid specific interferon-alpha2 expression, which will be administered to up to 27 patients affected by GBM who have an unmethylated MGMT promoter. Part A will evaluate the safety and tolerability of 5 escalating doses of Temferon and 3 different conditioning regimens in up to 27 patients, following first line treatment.
* DelveInsight's Glioblastoma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioblastoma treatment.
* The leading Glioblastoma Companies such as Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies and others.
* Promising Glioblastoma Therapies such as Axumin, Intravenous Solution, PolyMVA, MDNA55, Erlotinib HCl (OSI-774), BPM31510, Temozolomide (TMZ), and others.

Discover how the Glioblastoma treatment paradigm is evolving. Access DelveInsight's in-depth Glioblastoma Pipeline Analysis for a closer look at promising breakthroughs @ Glioblastoma Clinical Trials and Studies [https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Glioblastoma Emerging Drugs Profile

* Enzastaurin: Denovo BioPharma

DB102 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K, and AKT pathways that has been studied in more than 3,000 patients across a range of solid and hematological tumor types. DB102 was originally developed by Eli Lilly and for which Denovo has acquired worldwide rights. DB102 received Orphan Drug Designation in DLBCL and glioblastoma multiforme (GBM) from the FDA and EMA and Fast Track Designation from the FDA. DB102 is the world's first oral small-molecule kinase inhibitor targeting PKC. A retrospective analysis found that it has significant curative effects in high-risk DLBCL patients who are DGM1 positive. The company has initiated a biomarker guided Phase III clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma multiforme (GBM).

* Asunercept: Apogenix

CAN008 (asunercept) is a CD95-Fc fusion protein that binds to the CD95 ligand and blocks the interaction between the ligand and the endogenous CD95 receptor. CAN008 has a unique dual mechanism of action, inhibiting both the invasive growth and migration of tumor cells, as well as T-cell apoptosis, which enhances immune recognition of the cancer. Earlier asunercept glioblastoma multiforme (GBM) clinical trial data showed favorable safety and tolerability, prolonged survival and improved quality-of-life. Asunercept has been granted US FDA Orphan Drug Designation and Orphan Medicinal Product Designation by the European Medicines Agency (EMA) for GBM. It has also been accepted into the EMA's PRIME (Priority Medicines) program, which provides support to medicines that could address unmet medical needs. In China, CAN008 has been classified as a Class 1 New Drug by the National Medical Products Administration. CANbridge holds the rights to develop and commercialize CAN008 for any indication in Greater China and is currently conducting a CAN008 Phase II trial in GBM in China.

* Berubicin: CNS Pharmaceuticals

Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Glioblastoma.

* Azeliragon: Cantex

Azeliragon is an orally administered capsule, taken once daily, that inhibits interactions of the receptor for advanced glycation end products (known as RAGE) with certain ligands, including HMGB1 and S100 proteins in the tumor microenvironment. Azeliragon was discovered by and originally under development for Alzheimer's disease by vTv Therapeutics from which Cantex licensed worldwide rights to azeliragon. Currently, the drug is in Phase II stage of its clinical trial for the treatment of glioblastoma, brain metastasis, pancreatic cancer, breast cancer.

* VXM01: VAXIMM

VXM01 is an oral T-cell immunotherapy that is designed to activate T-cells to attack the tumor vasculature and, in several tumor types, attack cancer cells directly. VXM01 carries the vascular endothelial growth factor receptor-2 (VEGFR2), which is highly overexpressed on the tumor vasculature and on certain cancer cells as the target gene. The active, T-cell-mediated destruction of tumor vasculature cells leads to an increased infiltration of various immune cells into tumor tissue (inflammation). In preclinical studies, a murine analog VXM01 vaccine showed broad anti-tumor activity in different tumor types. This activity was linked to a VEGFR2-specific T-cell response and was accompanied by the destruction of the tumor vasculature and increased immune cell infiltration. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Glioblastoma.

* MB-101: Mustang Bio

MB-101 is a CAR-T cell therapy developed by Mustang Bio that targets IL13R2, a protein expressed on the surface of certain glioma cells. The therapy involves the infusion of CAR-T cells that are engineered to recognize and bind to IL13R2, leading to the activation and proliferation of these cells. This results in the killing of glioma cells and the potential for long-term remission. MB-101 has shown promising results in clinical trials, including achieving complete responses in two patients with high-grade glioma, and has been well-tolerated with manageable side effects. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Glioblastoma.

The Glioblastoma pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Treatment.
* Glioblastoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioblastoma market.

Get a detailed analysis of the latest innovations in the Glioblastoma pipeline. Explore DelveInsight's expert-driven report today! @ Glioblastoma Unmet Needs [https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Glioblastoma Companies

Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies and others.

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Glioblastoma Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Download DelveInsight's latest report to gain strategic insights into upcoming Glioblastoma Therapies and key Glioblastoma Developments @ Glioblastoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Glioblastoma Pipeline Report

* Coverage- Global
* Glioblastoma Companies- Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies and others.
* Glioblastoma Therapies - Axumin, Intravenous Solution, PolyMVA, MDNA55, Erlotinib HCl (OSI-774), BPM31510, Temozolomide (TMZ), and others.
* Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Glioblastoma drug development? Find out in DelveInsight's exclusive Glioblastoma Pipeline Report-access it now! @ Glioblastoma Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Glioblastoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Glioblastoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Enzastaurin: Denovo BioPharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Asunercept: Apogenix
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* MB-101: Mustang Bio
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Glioblastoma Key Companies
* Glioblastoma Key Products
* Glioblastoma- Unmet Needs
* Glioblastoma- Market Drivers and Barriers
* Glioblastoma- Future Perspectives and Conclusion
* Glioblastoma Analyst Views
* Glioblastoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glioblastoma-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies-by-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/surgical-lasers-market

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.